[ad_1]
Arkaitz Carracedo, a researcher at CIC bioGUNE, has secured a two million euro funding from the European Commission to study the vulnerability of prostate cancer over the next five years, announced today The scientific center
BILBAO. The young Dr. Carracedo joins the small group of researchers from around the world who manages to link two projects of the European ERC program, which supports research on excellence.
In addition to developing his research as an Ikerbasque professor at CIC bioGUNE, he coordinates a transnational team of researchers from the network of biomedical research centers in cancer (CIBERONC) and is badociate professor at the Université du Pays Basque.
After learning about the grant, Carracedo said receiving ERC support for further research "is not only very prestigious for us, but also allows us to move away from the abyss that would have forced to rely exclusively on scarce resources available. " national funds. "
The funded project proposes to address the mechanisms of progression of prostate cancer in an innovative perspective.
Dr. Carracedo explained in a statement that" the tumor cell lives and grows on a hostile terrain throughout its existence and develops adaptive mechanisms to persist over time. "Like living beings in nature, tumors also suffer from a natural selection process that makes only the most suitable cells survive. "
" Therefore, if we understand what are the most relevant adaptations for these cancer cells, we could develop treatments to block them, so that the tumors disappear, "he explained.
Carracedo recalled that the diagnosis and treatment of cancer have been significantly improved over the last 30 years, "but we face limitations based on understanding this process". We therefore propose to study tumor progression not according to properties. that they possess, but that the characteristics they must acquire remain throughout the different phases of the disease. "
The doctor will devote half of his two million euros" to recruitment and to the maintenance of excellent researchers within my laboratory, the rest being devoted to the acquisition of advanced equipment for the study of cancer, the purchase of consumables and the sub- service contracting ".
Source link
